SCHEMBL892553

SCHEMBL892553

CCc1ccc(N2CCC(C(=O)NCCc3c[nH]c4ccc(C)cc34)C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.54
MTNR1A P48039 2/20 0.52
MTNR1B P49286 2/20 0.52
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
SPR P35270 1/20 0.46
KDM4E B2RXH2 1/20 0.46
BCHE P06276 5/20 0.46
ACHE P22303 5/20 0.46
GFER P55789 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
GAA P10253 1/20 0.44
SNCA P37840 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892093 0.91 MTNR1A (0.52) KMT2AMTNR1AMTNR1BSMN1; SMN2GFER
SCHEMBL18601577 0.90 KMT2A (0.55) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL892306 0.87 SNCA (0.54) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL18601576 0.86 KMT2A (0.53) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL892580 0.83 MTNR1A (0.55) MTNR1AMTNR1BALDH1A1HPGDSMN1; SMN2
SCHEMBL892986 0.82 TSHR (0.50) MTNR1AMTNR1BSMN1; SMN2BCHEACHE
SCHEMBL892337 0.81 SNCA (0.53) KMT2AMEN1MTNR1AMTNR1BSMN1; SMN2
SCHEMBL10274768 0.81 MTNR1A (0.53) MTNR1AMTNR1BALDH1A1HPGDSMN1; SMN2
SCHEMBL891522 0.80 MTNR1A (0.55) MTNR1AMTNR1BSMN1; SMN2GFERTRPV1
SCHEMBL892549 0.80 MTNR1A (0.52) KMT2AMTNR1AMTNR1BALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440550-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2017-03-15 EP claimed
CN-102803252-B Be used for the treatment of indole amides derivative and the related compound thereof of neurodegenerative disorders K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2016-05-25 CN claimed
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders REMYND N.V. (BE) 2024-12-31 US disclosed
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-08-13 US disclosed
EP-3634407-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2020-04-15 EP disclosed
EP-3190109-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2020-02-19 EP disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
WO-2018206757-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2018-11-15 WO disclosed
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-11-06 US disclosed
EP-3190109-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven (BE) 2017-07-12 EP disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN KMT2A 2251/4885MEN1 3335/4885MTNR1A 67/4885
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN KMT2A 2306/4885MEN1 3452/4885MTNR1A 61/4885
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases SNCA, MAPT, NLN KMT2A 2251/4885MEN1 3335/4885MTNR1A 67/4885
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases SNCA, MAPT, NLN KMT2A 2306/4885MEN1 3452/4885MTNR1A 61/4885
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders PDE4A, PDE12, PDE2A KMT2A 1565/4885MEN1 2921/4885MTNR1A 1212/4885
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS PDE4A, PDE12, PDE2A KMT2A 1565/4885MEN1 2921/4885MTNR1A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.